Frequency of cytochrome P450 2C9 (CYP2C9) alleles in three ethnic groups in Malaysia

Asia-Pacific Journal of Molecular Biology and Biotechnology

Volumn 11, Issue 2, 2003, Pages 83-91

  Seng, Ku Chee ^a   Gin, Gan Gin ^a   Sangkar, J Vijaya ^a   Phipps, Maude Elvira ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

CYP2C9; Frequency; Genetic polymorphisms; Malaysian population; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; CYTOCHROME P450 2C9; WARFARIN;

ALLELE; ARTICLE; CAUCASIAN; CHINESE; COMPARATIVE STUDY; CONTROLLED STUDY; ETHNOLOGY; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALAYSIA; MOLECULAR TYPING; POLYMERASE CHAIN REACTION; POPULATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 1642409375     PISSN: 01287451     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ablin J, Cabili S, Lagziel A and Peretz H. 2002. Warfarin therapy in a patient homozygous for the CYP2C9*3 allele. Israel Medical Association Journal 4: 139-141
2. Aithal GP, Day CP, Kesteven PJL and Daly AK. 1999. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353: 111-119
3. Burian M, Grosch S, Tegeder I and Geisslinger G. 2002. Validation of new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. British Journal of Clinical Pharmacology 54: 518-521
4. Daly Ann K and King BP. 2003. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 13: 247-252
5. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJJ, Stein CM, Wilkinson GR and Schwarz UTEI. 2001. Identification and functional characterization of new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Molecular Pharmacology 60: 382-387
6. Goldstein JA. 2001. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. British Journal of Clinical Pharmacology 52: 349-355
7. Imai Jun, Ieiri Ichiro, Mamiya Kohsuke, Miyahara Sayaka, Furuumi Hiroyasu, Nanba Eiji, Yamane Masayuki, Fukumaki Yasuyuki, Ninomiya Hideaki, Tashiro Nobutada, Otsubo Kenji and Higuchi Shin. 2000. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 10: 85-89
8. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J and Goldstein JA. 2001. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11: 803-808
9. Lee CR, Goldstein JA and Pieper JA. 2002. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12: 251-263
10. Leung AYH, Chow HCH, Kwong YL, Lie AKW, Fung ATK, Chow WH, Yip ASB and Liang R. 2001. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 98: 2584-2587
11. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, Roitelman J, Harats D, Halkin H and Ezra D. 2001. Interindividual variability in sensitivity to warfarin - Nature or nurture? Clinical Pharmacology & Therapeutics 70: 159-164
12. Miller SA, Dykes DD, and Polesky HF. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research 16: 1215
13. Miyuki K, Ichiro I, Koshuke M, Akinori U, and Shun H. 1998. Genetic polymorphism of cytochrome P450s, CYP2C19 and CYP2C9 in a Japanese population. Therapeutic Drug Monitoring 20: 243-247
14. Nasu K, Kubota T, and Ishizaki T. 1997. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 7: 405-409
15. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E and Ingelman-Sundberg M. 2001. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and black African population. British Journal of Clinical Pharmacology 54: 447-450
16. Stubbins MJ, Harries LW, Smith G, Michael H. Tarbit and Wolf CR. 1996. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics; 6: 429-439
17. Sukru AA, Brockmoller J, Bauer S, Sachse C, Guzelbey P, Ongen Z, Muradiye N and Ivar R. 1999. Frequency of cytochrome P450 variants in a Turkish population and functional relevance for phenytoin. British Journal of Clinical Pharmacology 48: 409-415
18. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ and Goldstein JA. 1996. The role of the CYP2C9-Lue 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6: 341-349
19. Takahashi H and Echizen H. 2001. Pharmacogenetics of warfarin elimination and its clinical implications. Clinical Pharmacokinetics 40: 587-603
20. Taube J, Halsall D and Baglin T. 2000. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96: 1816-1819
21. van der Weide J, Steijns LSW, van Weelden MJM and de Haan K. 2001. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 11: 287-291
22. Wang SL, Huang JD, Lai MD and Tsai JJ. 1995. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5: 37-42
23. Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, Cha IJ and Shin JG. 2001. Frequency of cytochrome P4502C9 mutant alleles in a Korean population. British Journal of Clinical Pharmacology 51: 277-280